|
    XBIO U.S.: Nasdaq

    Xenetic Biosciences Inc.

    XBIOUS
    After Hours
    Last Updated: Sep 24, 2021 7:07 p.m. EDT Delayed quote

    $ 2.2000

    -0.02 -0.90%
    After Hours Volume: 711
    Close Chg Chg %
    $2.2200 -0.0200 -0.89%
    Advanced Charting
    Volume: 297.83K 65 Day Avg: 10M
    3% vs Avg
    2.1900 Day Range 2.2800
    0.7600 52 Week Range 5.8500

    Your Watchlists

    Customize eLesor

    Have Watchlists? Log in to see them here or sign up to get started.

    Symbol
    Company
    Price
    Chg/Chg %
    No Items in Watchlist

    There are currently no items in this Watchlist.

    Uh oh

    Something went wrong while loading Watchlist.

    Recently Viewed Tickers

    No Recent Tickers

    Visit a quote page and your recently viewed tickers will be displayed here.

    XBIO Overview

    Performance

    5 Day
    • -5.53%
    1 Month
    • -26.00%
    3 Month
    • 7.77%
    YTD
    • 8.82%
    1 Year
    • 143.96%

    Analyst Ratings

    • Sell
    • Under
    • Hold
    • Over
    • Buy
    Number of Ratings 1 Full Ratings

    Recent News

    Xenetic Biosciences Shares Rise 31% on Private Placement

    Xenetic Biosciences in Private-Placement Deal for 4.6M Shares

    Xenetic Biosciences stock more than quadruples on massive volume after partner's upbeat trial news

    Xenetic Biosciences started at buy with $2.50 stock price target at Maxim Group

    Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday

    on InvestorPlace.com

    Xenetic Biosciences (XBIO) Receives a Buy from H.C. Wainwright

    on TipRanks.com

    Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday

    on InvestorPlace.com

    Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday

    on InvestorPlace.com

    H.C. Wainwright Sticks to Its Buy Rating for Xenetic Biosciences (XBIO)

    on SmarterAnalyst

    H.C. Wainwright Sticks to Its Buy Rating for Xenetic Biosciences (XBIO)

    on SmarterAnalyst

    H.C. Wainwright Maintains a Buy Rating on Xenetic Biosciences (XBIO)

    on SmarterAnalyst

    Xenetic Biosciences (XBIO) Receives a Rating Update from a Top Analyst

    on SmarterAnalyst

    Xenetic Biosciences News: Why XBIO Stock Is Going Ballistic Today

    on InvestorPlace.com

    Maxim Group Releases a Buy Rating on Xenetic Biosciences (XBIO)

    on SmarterAnalyst

    Xenetic Biosciences (XBIO) Receives a Buy from H.C. Wainwright

    on SmarterAnalyst

    Xenetic Biosciences Inc.

    Xenetic Biosciences, Inc. is a biopharmaceutical company, which engages in the advancement of cell-based therapeutics to target the B-cell receptor on the surface of an individual patient’s malignant tumor cells. Its product pipeline includes XCart Platform and Polyxen. The company was founded on August 9, 2011 and is headquartered in Framingham, MA.